Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

References

• Atabi F, Mousavi Gargari SL, Hashemi M, Yaghmaei P. (2017). Doxorubicin loaded DNA aptamer linked myristilated chitosan nanogel for targeted drug delivery to prostate cancer. Iran J Pharm Res 16:35–49.
   PubMed Web of Science ®Google Scholar
• Bahreyni A, Yazdian-Robati R, Ramezani M, et al. (2017). Identification and imaging of leukemia cells using dual-aptamer-functionalized graphene oxide complex. J Biomater Appl 885328217712111.
   PubMed Web of Science ®Google Scholar
• Benito J, Ramirez MS, Millward NZ, et al. (2016). Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models. Clin Cancer Res 22:1687–98.
   PubMed Web of Science ®Google Scholar
• Bock LC, Griffin LC, Latham JA, et al. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564–6.
   PubMed Web of Science ®Google Scholar
• Bose P, Grant S. (2015). Rational combinations of targeted agents in AML. J Clin Med 4:634–64.
   PubMed Web of Science ®Google Scholar
• Broughton SE, Hercus TR, Hardy MP, et al. (2014a). Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. Cell Rep 8:410–19.
   PubMed Web of Science ®Google Scholar
• Broughton SE, Hercus TR, Nero TL, et al. (2014b). Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362. Acta Crystallogr F Struct Biol Commun 70:358–61.
   PubMed Web of Science ®Google Scholar
• Chang M, Yang CS, Huang DM. (2011). Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano 5:6156–63.
   PubMed Web of Science ®Google Scholar
• Chen K, Liu B, Yu B, et al. (2017). Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9. doi: 10.1002/wnan.1438
   Web of Science ®Google Scholar
• Cornelissen JJ, Blaise D. (2016). Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127:62–70.
   PubMed Web of Science ®Google Scholar
• Davis KA, Abrams B, Lin Y, Jayasena SD. (1996). Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res 24:702–6.
   PubMed Web of Science ®Google Scholar
• Ding Y, Gao H, Zhang Q. (2017). The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig 4:19.
   PubMedGoogle Scholar
• Douglas SM, Bachelet I, Church GM. (2012). A logic-gated nanorobot for targeted transport of molecular payloads. Science 335:831–4.
   PubMed Web of Science ®Google Scholar
• Du X, Ho M, Pastan I. (2007). New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 30:607–13.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Kramer M, Rollig C, et al. (2014). Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 4:e218.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Priceman SJ, Swiderski P, et al. (2014). CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest 124:2977–87.
   PubMed Web of Science ®Google Scholar
• Hao Z, Fan W, Hao J, et al. (2016). Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv 23:874–81.
   PubMed Web of Science ®Google Scholar
• Holmboe S, Hansen PL, Thisgaard H, et al. (2017). Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411. PLoS One 12:e0178286.
   PubMed Web of Science ®Google Scholar
• Jang D, Lee YM, Lee J, et al. (2017). Remission of lymphoblastic leukaemia in an intravascular fluidic environment by pliable drug carrier with a sliding target ligand. Sci Rep 7:40739.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Song C, Nangreave J, et al. (2012). DNA origami as a carrier for circumvention of drug resistance. J Am Chem Soc 134:13396–403.
   PubMed Web of Science ®Google Scholar
• Jing P, Cao S, Xiao S, et al. (2016). Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Cancer Lett 383:230–42.
   PubMed Web of Science ®Google Scholar
• Jung N, Dai B, Gentles AJ, et al. (2015). An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Commun 6:8489.
   PubMed Web of Science ®Google Scholar
• Khan M, Mansoor AE, Kadia TM. (2017). Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncol 13:523–35.
   PubMed Web of Science ®Google Scholar
• Li B, Zhao W, Zhang X, et al. (2016). Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem 24:5855–60.
   PubMed Web of Science ®Google Scholar
• Li F, Mei H, Xie X, et al. (2017). Aptamer-conjugated chitosan-anchored liposomal complexes for targeted delivery of erlotinib to EGFR-mutated lung cancer cells. AAPS J 19:814–26.
   PubMed Web of Science ®Google Scholar
• Li J, Pei H, Zhu B, et al. (2011). Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano 5:8783–9.
   PubMed Web of Science ®Google Scholar
• Liu FR, Jin H, Wang Y, et al. (2017). Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia. Drug Deliv 24:882–90.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhu M, Huang Y, et al. (2015). CD123 and its potential clinical application in leukemias. Life Sci 122:59–64.
   PubMed Web of Science ®Google Scholar
• Liu Z, Duan JH, Song YM, et al. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10:148.
   PubMed Web of Science ®Google Scholar
• Lyu Y, Chen G, Shangguan D, et al. (2016). Generating cell targeting aptamers for nanotheranostics using cell-SELEX. Theranostics 6:1440–52.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Forman SJ, Budde LE. (2015). T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484–8.
   PubMed Web of Science ®Google Scholar
• Medinger M, Lengerke C, Passweg J. (2016). Novel therapeutic options in acute myeloid leukemia. Leuk Res Rep 6:39–49.
   PubMedGoogle Scholar
• Mirian M, Khanahmad H, Darzi L, et al. (2017). Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharma Sci 12:88–98.
   PubMed Web of Science ®Google Scholar
• Moradi-Kalbolandi S, Habibi-Anbouhi M, Golkar M, et al. (2016). Development of a novel engineered antibody targeting human CD123. Anal Biochem 511:27–30.
   PubMed Web of Science ®Google Scholar
• Mosafer J, Abnous K, Tafaghodi M, et al. (2017). In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy. Eur J Pharm Biopharm 113:60–74.
   PubMed Web of Science ®Google Scholar
• Niraula S, Ocana A. (2016). Mechanism of drug resistance in relation to site of metastasis: meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. Cancer Treat Rev 50:168–74.
   PubMed Web of Science ®Google Scholar
• Pang L, Zhang C, Qin J, et al. (2017). A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles. Drug Deliv 24:83–91.
   PubMed Web of Science ®Google Scholar
• Petros RA, Desimone JM. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9:615–27.
   PubMed Web of Science ®Google Scholar
• Poolsup S, Kim CY. (2017). Therapeutic applications of synthetic nucleic acid aptamers. Curr Opin Biotechnol 48:180–6.
   PubMed Web of Science ®Google Scholar
• Prodeus A, Abdul-Wahid A, Fischer NW, et al. (2015). Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids 4:e237.
   PubMedGoogle Scholar
• Robertson DL, Joyce GF. (1990). Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344:467–8.
   PubMed Web of Science ®Google Scholar
• Schoumacher M, Burbridge M. (2017). Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr Oncol Rep 19:19.
   PubMed Web of Science ®Google Scholar
• Sett A, Borthakur BB, Sharma JD, et al. (2017). DNA aptamer probes for detection of estrogen receptor alpha positive carcinomas. Transl Res 183:104–20e2.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Mitchell A. (2015). AML evolution from preleukemia to leukemia and relapse. Best Pract Res Clin Haematol 28:81–9.
   PubMed Web of Science ®Google Scholar
• Short NJ, Ravandi F. (2016). The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia – a critical review. Expert Rev Hematol 9:529–34.
   PubMed Web of Science ®Google Scholar
• Soldevilla MM, Villanueva H, Bendandi M, et al. (2015). 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials 67:274–85.
   PubMed Web of Science ®Google Scholar
• Taghavi S, Ramezani M, Alibolandi M, et al. (2017). Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery. Cancer Lett 400:1–8.
   PubMed Web of Science ®Google Scholar
• Tauro S. (2016). The blind men and the AML elephant: can we feel the progress? Blood Cancer J 6:e424.
   PubMed Web of Science ®Google Scholar
• Thokala R, Olivares S, Mi T, et al. (2016). Redirecting specificity of T cells using the sleeping beauty system to express chimeric antigen receptors by mix-and-matching of VL and VH domains targeting CD123+ tumors. PLoS One 11:e0159477.
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–10.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu F, Wang Q, et al. (2017). A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells. Int J Pharm 529:531–42.
   PubMed Web of Science ®Google Scholar
• Wei Y, Gao L, Wang L, et al. (2017). Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy. Drug Deliv 24:681–91.
   PubMed Web of Science ®Google Scholar
• Xie J, Li Y, Song L, et al. (2017). Design of a novel curcumin-soybean phosphatidylcholine complex-based targeted drug delivery systems. Drug Deliv 24:707–19.
   PubMed Web of Science ®Google Scholar
• Xie LH, Biondo M, Busfield SJ, et al. (2017). CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J 7:e567.
   PubMed Web of Science ®Google Scholar
• Yeung CC, Radich J. (2017). Predicting Chemotherapy Resistance in AML. Curr Hematol Malig Rep. [Epub ahead of print]. doi: 10.1007/s11899-017-0378-x
   PubMed Web of Science ®Google Scholar
• Yoon S, Huang KW, Reebye V, et al. (2017). Aptamer-drug conjugates of active metabolites of nucleoside analogs and cytotoxic agents inhibit pancreatic tumor cell growth. Mol Ther Nucleic Acids 6:80–8.
   PubMedGoogle Scholar
• Zhang S, Lu C, Zhang X, et al. (2016). Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system. Drug Deliv 23:1838–45.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu X, Wang X, et al. (2016). CD123 redirected multiple virus-specific T cells for acute myeloid leukemia. Leuk Res 41:76–84.
   PubMed Web of Science ®Google Scholar
• Zhu G, Hu R, Zhao Z, et al. (2013a). Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J Am Chem Soc 135:16438–45.
   PubMed Web of Science ®Google Scholar
• Zhu G, Zheng J, Song E, et al. (2013b). Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 110:7998–8003.
   PubMed Web of Science ®Google Scholar